Avrohn Pharma (I) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 30-12-2024
- Paid Up Capital ₹ 0.50 M
as on 30-12-2024
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.48 Cr
as on 30-12-2024
- Satisfied Charges ₹ 6.00 M
as on 30-12-2024
- Revenue 32.98%
(FY 2022)
- Profit 5.88%
(FY 2022)
- Ebitda -9.11%
(FY 2022)
- Net Worth 32.87%
(FY 2022)
- Total Assets 22.75%
(FY 2022)
About Avrohn Pharma (I)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.48 Cr. The company has closed loans amounting to ₹6.00 M, as per Ministry of Corporate Affairs (MCA) records.
Neeta Gupta, Virender Gupta, and Abhishek Gupta serve as directors at the Company.
- CIN/LLPIN
U24119DL2012PLC232680
- Company No.
232680
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
12 Mar 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Avrohn Pharma (I)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neeta Gupta  | Director | 26-Mar-2022 | Current |
| Virender Gupta | Director | 12-Mar-2012 | Current |
| Abhishek Gupta | Director | 12-Mar-2012 | Current |
Financial Performance of Avrohn Pharma (I).
Avrohn Pharma (I) Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 32.98% increase. The company also saw a slight improvement in profitability, with a 5.88% increase in profit. The company's net worth Soared by an impressive increase of 32.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Avrohn Pharma (I)?
In 2022, Avrohn Pharma (I) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 06 Feb 2024 | ₹1.90 M | Open |
Canara Bank Creation Date: 06 Nov 2023 | ₹1.95 Cr | Open |
Canara Bank Creation Date: 19 Oct 2019 | ₹0.90 M | Open |
How Many Employees Work at Avrohn Pharma (I)?
Unlock and access historical data on people associated with Avrohn Pharma (I), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avrohn Pharma (I), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avrohn Pharma (I)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
